Optimal direct oral anticoagulant for upper gastrointestinal endoscopic submucosal dissection
Rivaroxaban might be an optimal DOAC for upper gastrointestinal ESD showing a lower risk for both ischemic stroke and delayed bleeding.
Authors
- Yutaka Hatayama
- Kiyohide Fushimi (ORCID: https://orcid.org/0000-0002-1894-0290)
- Kaname Uno (ORCID: https://orcid.org/0000-0002-4739-8795)
- Kenji Fujimori (ORCID: https://orcid.org/0000-0003-2199-7172)
- Tomoyuki Koike (ORCID: https://orcid.org/0000-0001-6472-3257)
- Atsushi Masamune (ORCID: https://orcid.org/0000-0001-7184-7282)
- Yohei Ogata (ORCID: https://orcid.org/0000-0002-5762-2156)
- Kunio Tarasawa (ORCID: https://orcid.org/0000-0002-7442-7926)
- Akira Imatani (ORCID: https://orcid.org/0000-0003-1885-9983)
- Xiaoyi Jin (ORCID: https://orcid.org/0000-0003-4690-9570)
- Hiroko Abe (ORCID: https://orcid.org/0000-0003-1779-6212)
- Yoshitaka Ono (ORCID: https://orcid.org/0000-0002-8247-7245)
- Waku Hatta (ORCID: https://orcid.org/0000-0001-9717-0281)
- Isao Satō
- Shin Hamada
- Masahiro Saito (ORCID: https://orcid.org/0000-0001-7051-1517)
Institutions
- Tokyo Medical and Dental University (JP)
- Tohoku University (JP)
Publication Details
- Journal
- Journal of Gastroenterology
- Published
- 2024-11-27
- DOI
- https://doi.org/10.1007/s00535-024-02171-2
- Citations
- 5
- Primary Topic
- Gastric Cancer Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Health Promotion Administration, Ministry of Health and Welfare